OPCM
GILD icon

Osborne Partners Capital Management’s Gilead Sciences GILD Stock Holding History

Osborne Partners Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,991
Closed -$257K – 211
2022
Q4 		$257K Buy
+2,991
New +$237K 0.02% 188
2015
Q2 		– Sell
-2,645
Closed -$260K – 178
2015
Q1 		$260K Buy
+2,645
New +$269K 0.03% 166

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osborne Partners Capital Management's GILD Position: Q1 2023 in Review

Osborne Partners Capital Management sold out of Gilead Sciences (GILD) in Q1 2023, closing a stake of 2,991 shares — an estimated $257K sold.

Osborne Partners Capital Management first reported a position in GILD in Q1 2015 and held it in 2 quarters. The position peaked at $260K in Q1 2015. 1,735 funds tracked by Wall St. Rank hold GILD as of Q1 2023.

  • Osborne Partners Capital Management reported no remaining Gilead Sciences position as of Q1 2023 after selling out during the quarter.
  • Osborne Partners Capital Management sold 2,991 Gilead Sciences shares in Q1 2023, an estimated $257K.
  • Osborne Partners Capital Management first reported a position in Gilead Sciences in Q1 2015 and held it in 2 quarters.
  • Osborne Partners Capital Management's Gilead Sciences position peaked at $260K in Q1 2015.
  • 1,735 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2023.

Based on Osborne Partners Capital Management's 13F filing for Q1 2023, filed 24 Apr 2023.